tirzepatide diabetic retinopathy risk Risk: Monitoring and Safety Comparative ocular outcomes of tirzepatide
Description
As this report aims to support clinicians in reviewing major mechanistic studies of the approved molecule tirzepatide, it does not include studies of other GIPRA/GLP-1RAs under investigation
The strange part
Smaller dose increases mean smaller disruptions to the GI system, which translates to fewer and milder side effects
If you experience these symptoms, discuss a dose reduction with your provider rather than simply pushing through
The introductory rate draws people in
this is called pulmonary aspiration and can be life-threatening
